C1Q

Complement C1q

Score: 0.624 Price: $0.62 Low Druggability Status: active Wiki: C1Q

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

1361

DEBATES

3D Protein Structure

🧬 C1Q — PDB 1PK6 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Low

Score: 0.36

Clinical Stage

Approved

Target Class

Signaling Protein

Safety

0.45

Druggability Analysis

Drug Development0.75

Structural Tractability0.30

Target Class0.50

Safety Profile0.45

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (1 compounds)

1 Approved

Therapeutic Areas:

Neurodegeneration/Alzheimer's disease Neuroinflammation Synaptic dysfunction Cold agglutinin disease Complement-mediated autoimmune disorders Neuropsychiatric disorders with neuroinflammatory component

Druggability Rationale: C1Q demonstrates medium druggability (0.55) supported by the clinical success of Sutimlimab, an approved monoclonal antibody, validating the target for therapeutic intervention. As a secreted signaling protein in the complement cascade, C1Q is inherently druggable via antibody-mediated neutralization, though small-molecule inhibitors face challenges due to the lack of a classical ATP-binding pocket and the protein's structural complexity.

Mechanism: Complement cascade inhibitor or antibody-mediated neutralization

Drug Pipeline (1 compounds)

1 Approved

Known Drugs:

Sutimlimab (approved) — Cold agglutinin disease

Structural Data:

PDB —AlphaFold ✓Cryo-EM ✓

Binding Pocket Analysis:

C1Q lacks a traditional small-molecule binding pocket, instead functioning as a scaffold protein with multiple protein-protein interaction surfaces for C1r/C1s binding and target recognition. Therapeutic engagement relies primarily on monoclonal antibodies targeting conformational epitopes or functional domains (such as the collagen-like region), as evidenced by Sutimlimab's mechanism; structural characterization via AlphaFold and cryo-EM supports antibody design but limits small-molecule optimization strategies.

🧬 3D Protein Structure

🧬 C1Q — PDB 1PK6 Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity is a critical challenge given C1Q's central role in both pathological complement activation and physiological immune homeostasis; therapeutic targeting must preserve beneficial functions (pathogen clearance, apoptotic cell clearance) while blocking aberrant neuroinflammatory signaling. Antibody-based approaches offer superior selectivity through epitope selection, whereas pan-complement inhibitors risk broad immunosuppression.